Live In Play®
Updated: 23-Jul-21 16:34 ET
INCY:  Incyte: US FDA cannot approve co's application for its retifanlimab drug in its present form  (79.30 +0.68)
  • The letter states that additional data are needed to demonstrate the clinical benefit of retifanlimab for the treatment of patients with advanced or metastatic SCAC.
  • Co stated, "While we are not surprised with the FDA decision given the ODAC recommendation, we are disappointed. We remain committed to advancing science to find solutions for patients with unmet medical needs, and we will ensure close coordination with the FDA in order to address feedback and determine next steps for the review of retifanlimab."
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.